Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Firms / Frazier Life Sciences Management, LP

Frazier Life Sciences Management, LP

Private equity with venture activity · probablePalo Alto, CAfrazierls.comSEC registered investment adviser

Frazier Life Sciences is a longstanding biotech investment firm with venture and public strategies partnering with and building companies developing novel therapeutics.

registered adviser; venture funds are 38% of 8 private funds

Importance
46
elevated
Active deployment
0
low
Emerging
0
low
Completeness
88
high
Freshness
100
high
Research priority
3
low
Identity and regulatory footprint
Headquarters
Palo Alto, CAadviserinfo.sec.gov
Office address
1001 PAGE MILL ROAD, BUILDING 4, SUITE 200B, Palo Alto, CA, 94304adviserinfo.sec.gov
Business phone
650-325-5156adviserinfo.sec.gov
SEC adviser type
registered investment adviseradviserinfo.sec.gov
SEC exemption claimed
unknown
Latest Form ADV
Mar 31, 2026
Private funds reported
8 (4 venture capital funds)adviserinfo.sec.gov
Private fund gross assets
$7.0Badviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
Regulatory AUM
$7.0Bthe adviser's RAUM, a regulatory measure, never a fund size
Employees
64
Owners on Schedule A
Galena Holdings, LLC (Limited Partner), D; Frazier Life Sciences Management, L.L.C. (General Partner), NA; Topper Family, LLC (Limited Partner), D
business phone
650-325-5156adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
1 observed deals
Stated (the firm’s website)
Sectors
healthcare, biotech
Stages
seed
Geography
boston, seattle
Check size
not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors
Other Technology 100%
lead rate n/afollow-on rate n/anew logos, 12 months 0
Funds and vehicles
6 reported
VehicleTypeVintageLifecycleReported GAVOwnersForm D soldLatest Form D
Frazier Life Sciences X, L.P.Fund · ADV: Private Equity Fund2022 adv first reportedActive deployment$567M
Mar 30, 2024
72$0
of $617M
Dec 17, 2019
Frazier Life Sciences Xi, L.P.Fund2022 form d first saleActive deployment$316M
Mar 30, 2024
99$960M
of $960M
Mar 18, 2022
Frazier Life Sciences Ix, L.P.Fund2017 form d first saleHarvest$404M
Mar 30, 2024
54$419M
of $419M
Nov 1, 2017
Frazier Life Sciences Viii, L.P.Fund2015 form d first saleHarvest$161M
Mar 30, 2024
45$262M
of $262M
Oct 29, 2015
Frazier Healthcare Vii-A, L.P.Feeder or parallel · ADV: Private Equity Fund2013 form d first saleHarvest$16.1M
Mar 30, 2024
5$82.5M
of $82.5M
May 8, 2013
Frazier Life Sciences XII, L.P.FundunknownUnknownunknownunknown$0Mar 17, 2025
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
68 current, 18 departed
James Brush
General Partner & Portfolio Manager · since Nov 1, 2021
General partner
Wendy Cihak
Investor Relations Coordinator and Executive Assistant
Investor relations
Duncan Johnson
Controller, Public Fund Accounting
Platform and operations
Gordon Empey
Partner, COO and General Counsel
Platform and operations
Helen Kang
Senior Manager, Trade Operations and Compliance
Platform and operations
Jennifer Martin
Chief Financial Officer and Partner
Platform and operations
Steve Ray Bailey
Chief Financial Officer & Chief Compliance Officer · since Nov 1, 2021
Platform and operations
Ali Jackson
Vice President and Counsel, Public Funds
Vice president
18 departed (kept with end dates)
Investments on record
1 edges, 1 companies, 1 partner-attributed
CompanyRoundRolePartnerRound sizeThis investorDateSource
Sudo Biosciences, Inc.board seatunknown · boardDaniel Estes (strongly supported)unknownunknownFeb 15, 2024Inference SEC EDGAR Form D data sets (quarterly)
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
0 relationships from shared deals, counted for the whole firm
No co-investor relationship yet: these are derived only from rounds and portfolio listings the graph has seen both investors on.
Limited partners
3 disclosed
Timeline
21 dated events
  1. Sep 16, 2026
    W. Michael Gallatin (Senior Advisor) no longer on the team page of Frazier Life Sciences Management, LP
  2. Sep 16, 2026
    Roger Ulrich (Senior Advisor) no longer on the team page of Frazier Life Sciences Management, LP
  3. Sep 16, 2026
    Michael Varney (Senior Advisor) no longer on the team page of Frazier Life Sciences Management, LP
  4. Sep 16, 2026
    James Bristol (Senior Advisor) no longer on the team page of Frazier Life Sciences Management, LP
  5. Sep 16, 2026
    Don Frail (Senior Advisor) no longer on the team page of Frazier Life Sciences Management, LP
  6. Sep 16, 2026
    Bryan A. Irving (Senior Advisor) no longer on the team page of Frazier Life Sciences Management, LP
  7. Sep 16, 2026
    Bruce Roth (Senior Advisor) no longer on the team page of Frazier Life Sciences Management, LP
  8. Sep 16, 2026
    Bhaskar Chaudhuri (Senior Advisor) no longer on the team page of Frazier Life Sciences Management, LP
  9. Sep 16, 2026
    Angie You (Senior Advisor) no longer on the team page of Frazier Life Sciences Management, LP
  10. Sep 16, 2026
    Zaneta Odrowaz (Vice President of Company Creation) no longer on the team page of Frazier Life Sciences Management, LP
  11. Sep 16, 2026
    Lauren Mifflin (Principal of Company Creation) no longer on the team page of Frazier Life Sciences Management, LP
  12. Sep 16, 2026
    Christopher Aakre (Principal of Company Creation) no longer on the team page of Frazier Life Sciences Management, LP
  13. Sep 16, 2026
    Maria Fardis (Venture Partner) no longer on the team page of Frazier Life Sciences Management, LP
  14. Sep 16, 2026
    Xinghuo Li (Senior Associate) no longer on the team page of Frazier Life Sciences Management, LP
  15. Sep 16, 2026
    Angel Martin (Vice President) no longer on the team page of Frazier Life Sciences Management, LP
  16. Sep 16, 2026
    Anna H. Chen (Partner) no longer on the team page of Frazier Life Sciences Management, LP
  17. Sep 16, 2026
    Aditya Kohli (Partner) no longer on the team page of Frazier Life Sciences Management, LP
  18. Sep 16, 2026
    Daniel Estes (General Partner) no longer on the team page of Frazier Life Sciences Management, LP
  19. Jul 25, 2025
    NYSCRF commits $110,000,000 to Frazier Life Sciences XII, L.P. (“Frazier LS”) (Frazier Life Sciences Management, L.P.), closed 2025-07-25, existing relationship
  20. Mar 31, 2022
    Frazier Life Sciences Xi, L.P. first reported on Form ADV by Frazier Life Sciences Management, LP (Venture Capital Fund), GAV $987,237,178
  21. Nov 18, 2021
    Frazier Life Sciences Management, LP first filed Form ADV (IA)
Classification history
  1. Sep 12, 2026
    Private equity with venture activity (probable, 75%, cls-1)
    registered adviser; venture funds are 38% of 8 private funds
Evidence
47 observations from 3 sources
Every observation behind this profile, with its source, date and class
FactValueEffectiveClassSource
Why admittedvc_funds_reportedMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
SEC adviser typeregistered_investment_adviserMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
SEC adviser typeregistered_investment_adviserMar 30, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
First Form ADV filing2021-11-18Mar 30, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Adv history loadedadv-hist-1Sep 12, 2026FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Latest Form ADV filing2026-03-31Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Latest Form ADV filing2024-03-30Mar 30, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
SEC statusApprovedMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
SEC status effective2021-12-17Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Venture share of reported funds0Mar 30, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Business phone650-325-5156Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Business phone650-325-5156Mar 30, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
DescriptionFrazier Life Sciences is a longstanding biotech investment firm with venture and public strategies partnering with and building companies developing novel therapeutics.
meta description
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
DescriptionFrazier Life Sciences is a longstanding biotech investment firm with venture and public strategies partnering with and building companies developing novel therapeutics.
meta description
Sep 14, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Employees64Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Employees53Mar 30, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
HeadquartersPalo Alto, CAMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
HeadquartersPalo Alto, CAMar 30, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Office address1001 PAGE MILL ROAD, BUILDING 4, SUITE 200B, Palo Alto, CA, 94304Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Office address1001 PAGE MILL ROAD, BUILDING 4, SUITE B, Palo Alto, CA, 94304Mar 30, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Legal formLimited PartnershipMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
PE funds reported3Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Portfolio pagehttps://frazierls.com/portfolio/
0 entries read
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Portfolio pagehttps://frazierls.com/portfolio/
0 entries read
Sep 14, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Private funds reported8Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Private funds reported8Mar 30, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Private fund gross assets (reported)$7.0BMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Private fund gross assets (reported)$2.7BMar 30, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Regulatory AUM (adviser, not fund size)$7.0BMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Regulatory AUM (adviser, not fund size)$3.6BMar 30, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Stated geographyboston,seattle
geography words on the home page
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Stated geographyboston,seattle
geography words on the home page
Sep 14, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Stated sectorshealthcare,biotech
sector words on the home page
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Stated sectorshealthcare,biotech
sector words on the home page
Sep 14, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Stated stagesseed
stage words on the home page
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Stated stagesseed
stage words on the home page
Sep 14, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Team pagehttps://frazierls.com/team/
62 name/title pairs read
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Team pagehttps://frazierls.com/team/
50 name/title pairs read
Sep 14, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Venture funds reported4Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Venture funds reported3Mar 30, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Websitehttps://www.frazierls.comMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Websitehttps://www.frazierls.comMar 30, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)